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Abstract
Immunoregulatory cytokine interleukin-10 (IL-10) is elevated in sera from patients with systemic lupus erythematosus (SLE)
correlating with disease activity. The established association of IL10 with SLE and other autoimmune diseases led us to fine
map causal variant(s) and to explore underlying mechanisms. We assessed 19 tag SNPs, covering the IL10 gene cluster
including IL19, IL20 and IL24, for association with SLE in 15,533 case and control subjects from four ancestries. The previously
reported IL10 variant, rs3024505 located at 1 kb downstream of IL10, exhibited the strongest association signal and was
confirmed for association with SLE in European American (EA) (P = 2.761028, OR = 1.30), but not in non-EA ancestries. SNP
imputation conducted in EA dataset identified three additional SLE-associated SNPs tagged by rs3024505 (rs3122605,
rs3024493 and rs3024495 located at 9.2 kb upstream, intron 3 and 4 of IL10, respectively), and SLE-risk alleles of these SNPs
were dose-dependently associated with elevated levels of IL10 mRNA in PBMCs and circulating IL-10 protein in SLE patients
and controls. Using nuclear extracts of peripheral blood cells from SLE patients for electrophoretic mobility shift assays, we
identified specific binding of transcription factor Elk-1 to oligodeoxynucleotides containing the risk (G) allele of rs3122605,
suggesting rs3122605 as the most likely causal variant regulating IL10 expression. Elk-1 is known to be activated by
phosphorylation and nuclear localization to induce transcription. Of interest, phosphorylated Elk-1 (p-Elk-1) detected only in
nuclear extracts of SLE PBMCs appeared to increase with disease activity. Co-expression levels of p-Elk-1 and IL-10 were
elevated in SLE T, B cells and monocytes, associated with increased disease activity in SLE B cells, and were best
downregulated by ERK inhibitor. Taken together, our data suggest that preferential binding of activated Elk-1 to the IL10
rs3122605-G allele upregulates IL10 expression and confers increased risk for SLE in European Americans.
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Introduction
The gene cluster that includes interleukin 10 (IL10), IL19, IL20
and IL24 is located on chromosome 1q31-32, a genomic region
that is linked with susceptibility to systemic lupus erythematosus
(SLE, OMIM 152700) [1,2]. Recent genome-wide association
(GWA) and follow-up replication studies in European ancestry
have identified an association between the minor allele of
rs3024505, a SNP located at 1 kb downstream of IL10, and
increased risk for SLE [3], inflammatory bowel disease (IBD)
including both Crohn’s disease (CD) [4] and ulcerative colitis (UC)
[5,6], and decreased risk for type 1 diabetes [7,8]. In addition,
SNPs in the second intron (rs1518111) and the promoter region
(rs1800871) of IL10 have been reported to be associated with
Behc¸et’s disease (BD) in GWAS of Turks [9] and Japanese [10].
These findings indicate IL10 as a common susceptibility locus
shared by SLE and several other autoimmune diseases.
Dysregulation of IL-10 family cytokines contributes to autoim-
mune disease and tissue damage (reviewed in [11]). IL-10 is an
important immunoregulatory cytokine with a wide variety of
functions in T cells, B cells, natural killer cells, dendritic cells and
macrophages [12]. The observations of elevated serum IL-10
levels in SLE patients correlating with increased disease activity
[13,14], and promising findings of anti-IL-10 monoclonal
antibody treatment in patients with SLE [15] support a pivotal
role for IL-10 in the pathogenesis of SLE. Of interest, elevated IL-
10 levels were also reported in first-degree relatives of SLE patients
[16,17], suggesting that levels of IL10 expression may be
determined genetically.
In this study, we fine mapped the IL10 gene cluster for genetic
association with SLE in 15,533 case and control subjects from four
diverse ancestries, identified a causal variant rs3122605 at IL10 59
upstream using both genetic and functional assays, and explored
the underlying molecular mechanism in explaining the elevated
IL-10 levels in patients with SLE associated with increased disease
activity.
Results
Association of four IL10 SNPs with SLE susceptibility in
European Americans
To fine map the IL10 gene cluster, we genotyped 19 tag SNPs in
15,533 case and control subjects from four ancestries, including
European American (EA, 3,820 cases vs. 3,412 controls), African
American (AA, 1,670 vs. 1,904), Asian (AS, 1,252 vs. 1,249) and
Amerindian/Hispanic (HS, 1,445 vs. 781). Each SNP was assessed
for the association with SLE susceptibility under a logistic
regression model adjusted for gender and global ancestry
(Figure 1A). In the largest EA dataset, rs3024505 located at 1 kb
downstream of IL10 exhibited the strongest association with SLE
(minor allele frequency of 18.2% in cases vs. 14.8% in controls,
P= 2.761028, OR [95%CI] = 1.30 [1.19–1.43]), which exceeded
the GWAS significance level of P,561028 (Table S1). To identify
Author Summary
Systemic lupus erythematosus (SLE), a debilitating auto-
immune disease characterized by the production of
pathogenic autoantibodies, has a strong genetic basis.
Variants of the IL10 gene, which encodes cytokine
interleukin-10 (IL-10) with known function of promoting
B cell hyperactivity and autoantibody production, are
associated with SLE and other autoimmune diseases, and
serum IL-10 levels are elevated in SLE patients correlating
with increased disease activity. In this study, to discover
SLE-predisposing causal variant(s), we assessed variants
within the genomic region containing IL10 and its gene
family member IL19, IL20 and IL24 for association with SLE
in case and control subjects from diverse ancestries. We
identified SLE-associated SNP rs3122605 located at 9.2 kb
upstream of IL10 as the most likely causal variant in
subjects of European ancestry. The SLE-risk allele of
rs3122605 was dose-dependently associated with elevated
IL10 expression at both mRNA and protein levels in
peripheral blood samples from SLE patients and controls,
which could be explained, at least in part, by its
preferential binding to Elk-1, a transcription factor activat-
ed in B cells during active disease of SLE patients. Elk-1-
mediated IL-10 overexpression could be downregulated by
inhibiting activation of mitogen-activated protein kinases,
suggesting a potential therapeutic target for SLE.
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additional SLE-associated SNPs, we performed SNP imputation
using 1000 Genomes Project data as a reference. In EA, a total of
109 well-imputed SNPs spanning 154 kb from IL10 downstream
to FAIM3 were assessed for association with SLE. Of them, three
imputed SNPs (rs3122605, rs3024493 and rs3024495 located at
9.2 kb upstream, intron 3 and 4 of IL10, respectively), which were
in tight linkage disequilibrium (LD, r2.0.9) with the genotyped
SNP rs3024505, were strongly associated with SLE and remained
significant after Bonferroni correction (rs3122605: P= 1.361028,
OR = 1.34 [1.21–1.48]; rs3024493: P= 5.061028, OR = 1.29
[1.18–1.42]); rs3024495: P= 1.061027, OR = 1.29 [1.17–1.41])
(Figure 1B and Table S1). None of the genotyped or imputed
SNPs was significantly associated with SLE in three non-European
datasets including AS, AA and HS after Bonferroni correction
(Table S2). These data confirmed that IL10 is a risk locus for SLE
in EA, and thus we subsequently focused on EA only to identify
the causal variant(s).
IL10 promoter SNPs rs1800872 (also named as 2592T/G),
rs1800871 (2819G/A) and rs1800896 (21082T/C), which were
identified to be associated with elevated IL-10 production and
SLE susceptibility in some, but not all of previous studies (reviewed
in [18,19]), showed nominal association with SLE in our EA
dataset (Table S1). The BD-associated SNP rs1518111 showing
effect on decreased IL-10 levels [9] was not associated with SLE in
EA (Table S1). We performed haplotypic analysis to investigate
relationships between these four previously reported SNPs and
rs3024505, rs3024495, rs3024493 and rs3122605. Only the
haplotype H4 carrying risk alleles of rs3024505, rs3024495,
rs3024493 and rs3122605 was strongly associated with SLE
(frequency of 16.8% in cases vs. 13.6% in controls, P= 1.361027)
(Figure 1D).
Due to strong LD among rs3122605, rs3024493, rs3024495 and
rs3024505 in EA ancestry, their associations with SLE were highly
correlated and could not be distinguished from each other using
the conditional haplotype-based association test (Table S1).
Conditioning on rs3122605, rs3024493, rs3024495 and
rs3024505, respectively, association signals (P,0.05) of all other
SNPs within the IL10 gene cluster were completely eliminated
(Table S1), suggesting that these four SNPs within tight LD could
capture all associations of the IL10 cluster region with SLE in EA.
Of note, searching +/2200 kb of IL10 based on the 1000
Genomes Project data, we found that rs61815643 located at
10.3 kb upstream of IL10 was also in strong LD with rs3122605
(r2 = 0.9) in European subjects, which suggested that this SNP
might account for association signals detected within the IL10 gene
cluster. However, because the imputation quality of rs61815643
did not reach the threshold of information score .0.9, it was not
included for association test in this study.
Taken together, our data provide evidence supporting IL10 as a
risk locus for SLE in EA and the underlying causal variant(s) might
be or tagged by rs3122605, rs3024505, rs3024495 and rs3024493.
Dose-dependent association between SLE-risk allele and
elevated IL10 expression levels
To explore potential functional consequences of the SLE-
associated SNPs (rs3122605, rs3024493, rs3024495 and
rs3024505), we assessed their genetic effects on influencing IL10
expression. IL10 mRNA levels in peripheral blood mononuclear
cells (PBMC) and IL-10 protein levels in plasma from EA subjects
were measured by quantitative real-time PCR and ELISA,
respectively. Using rs3122605 as a surrogate of the other three
Figure 1. SNPs of the IL10 gene cluster associated with SLE in European Americans. (A) Association of 19 genotyped SNPs with SLE in EA
(red), AA (yellow), AS (blue) and HS (green). Allelic P value (2log10P) of each SNP was plotted against its genomic position. (B) Association of 19
genotyped and an additional 109 imputed SNPs with SLE in EA. Genotyped and imputed SNPs were indicated as circles and triangles, respectively.
Based on its pairwised LD strength with rs3024505, each SNP was highlighted as red (r2.0.9) or grey (r2,0.9). (C) Genomic structure of the IL10 gene
cluster and the location of each SNP. (D) Haplotypic analysis in EA. Haplotypes were constructed using four SLE-associated SNPs shown in Figure 1B
(rs3024505, rs3024495, rs3024493 and rs3122605), three previously reported SLE-associated SNPs (rs1800872, rs1800871 and rs1800896 in the
promoter of IL10) and rs1518111 (the T allele associated with Bechet’s disease). Risk alleles of four SLE-associated SNPs shown in Figure 1B were
bolded and italicized.
doi:10.1371/journal.pgen.1003870.g001
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SNPs, we compared IL10 expression levels among subjects
carrying different genotypes of rs3122605. In control subjects,
the SLE-risk (G) allele of rs3122605 was dose-dependently
associated with elevated IL10 expression at both mRNA (n = 55;
P= 0.001, R2 = 0.18 in linear regression) and protein (n = 116;
P= 3.361027, R2 = 0.21) levels (Figure 2). Consistently, dose-
dependent association of the risk allele with elevated IL10
expression was also observed in patients with SLE at both mRNA
(n = 58; P= 6.461026, R2 = 0.31) and protein (n = 132;
P= 1.461026, R2 = 0.16) levels (Figure 2).
Compared to healthy controls, higher IL10 expression was
observed in patients with SLE carrying the same genotype at both
mRNA (genotype AA: P= 1.361024, AG: P= 4.361024, GG:
P= 3.961025, cases vs. controls in t test) and protein (AA:
P= 4.661024, AG: P= 4.961026, GG: P= 0.047) levels (Figure 2),
probably due to the activated immune status of SLE patients.
Figure 2. Dose-dependent association of rs3122605 risk G-allele with elevated levels of IL10 mRNA and protein. IL10 mRNA (A) and
protein levels (B) were measured in PBMCs and plasma from EA SLE patients and healthy controls, respectively. Each symbol represents an individual
and horizontal lines indicate mean 6 SEM values.
doi:10.1371/journal.pgen.1003870.g002
Figure 3. Preferential binding of rs3122605-risk allele to Elk-1, which is a transcription factor activated in peripheral lymphocytes
of SLE patients. (A) Specific binding of transcription factor Elk-1 to the risk allele of rs3122605 in EMSA. Mobility-shift bands were produced by the
oligodeoxynucleotide probes containing the risk allele of rs3122605 incubated with nuclear extracts of peripheral blood lymphocytes from active SLE
patients, and the addition of anti-Elk-1 antibody generated a super shift band. The data are representative of two independent experiments. (B, C)
Nuclear retention of activated p-Elk-1 in PBMCs from SLE patients. The presence of Elk-1 and p-Elk-1 in nuclear (B) and cytoplasmic (C) extracts of
PBMCs from SLE patients and healthy controls was measured using Western blot. Lamin B (B) and b-actin (C) were used as loading controls. The data
are representative of two independent experiments.
doi:10.1371/journal.pgen.1003870.g003
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The risk allele of rs3122605 creates a novel binding site
to transcription factor Elk-1 at 59upstream of IL10
We hypothesized the presence of transcription factors activated
in SLE patients upregulating IL10 expression and prepared
nuclear extracts of peripheral blood lymphocytes from active
SLE patients (defined as SLEDAI score$4) [20,21] to perform
electrophoretic mobility shift assays (EMSA) for testing allelic
differences in transcription factor binding conferred by the SLE-
associated SNPs rs3122605, rs3024505, rs3024495 and
rs3024493. Because we could not exclude the possibility that
rs61815643 is a SLE-risk SNP affecting IL10 expression, it was
also tested by EMSA.
Upon incubation with nuclear extracts, specific mobility-shift
bands were only detected using the oligodeoxynucleotide probe
containing the risk, but not the non-risk allele of rs3122605
(Figure 3A). Of interest, no specific binding of nuclear proteins was
observed with the oligodeoxynucleotide probes containing either
the risk or the non-risk allele of rs3024505, rs3024493, rs3024495
and rs61815643 (Figure S1). In silico analysis using the program
TFSEARCH indicated that the risk allele of rs3122605 might
create a novel binding site of the transcription factor Elk-1 (ETS-
like transcription factor 1). We validated this prediction by
showing that the addition of polyclonal rabbit IgG anti-ElK-1
antibody produced a super shift band only to the probe containing
the risk but not the non-risk allele of rs3122605 in EMSA
(Figure 3A).
Taken together, these data showed that rs3122605, the risk
allele of which binds to Elk-1 in peripheral blood lymphocytes
from SLE patients with active disease, is more likely to be the
causal variant upregulating IL10 expression than the other four
candidate SNPs.
Aberrant activation of Elk-1 in the nuclei of PBMCs from
patients with SLE
Elk-1 is activated through phosphorylation and the phosphor-
ylated Elk-1 (p-Elk-1) translocates into the nucleus to induce gene
transcription [22]. To investigate the role of Elk-1 in SLE, we
compared the distribution and activation of Elk-1 in PBMCs
between SLE cases (n = 4) and healthy controls (n = 4) using
Western blot. The amount of total Elk-1 was higher in nuclear
(Figure 3B) but lower in cytoplasmic extracts (Figure 3C) of cases
than controls. Of interest, p-Elk-1 was detected only in nuclear
extracts of cases but not in controls (Figure 3B) and not in
cytoplasmic extracts of either cases or controls (Figure 3C). These
data suggest that Elk-1 is aberrantly activated and accumulates in
nuclei of SLE PBMCs. Furthermore, the amount of total Elk-1
and p-Elk-1 appeared to be increased in SLE patients with higher
SLEDAI scores (Figure 3B).
Co-expression of IL-10 and p-Elk-1 increases with SLE
disease activity in B cells and could be best down-
regulated by ERK inhibitor
Using flow cytometry, we quantified the co-expression of IL-10
and p-Elk-1 in specific cell subsets of PBMCs including CD3+ T
cells, CD19+ B cells and CD14+ monocytes from healthy controls
and SLE patients and showed representative data plotted in two-
dimensional dot plots in Figure 4A. Compared to healthy controls
(n = 3), percentages of IL-10+p-Elk-1+ cells were significantly
increased in B (n = 11), T cells (n = 12) and monocytes (n = 12)
from SLE patients (Student’s t-test: P= 0.013, 0.012 and 0.012,
respectively, Figure 4B). Active SLE patients had significantly
elevated IL-10+p-Elk-1+ double positive B cells compared to non-
active SLE patients (n = 7 vs. 4, P= 0.038). Similar trends for
association with SLE disease activity were detected in IL-10+p-Elk-
1+ T cells and monocytes, but the difference was not statistically
significant (P= 0.74 and 0.57, respectively).
Elk-1 is known to be activated by mitogen-activated protein
kinases (MAPK), including ERK (extracellular-signal-regulated
kinases), JNK (c-Jun N-terminal kinases) and p38. We wondered
which MAPK inhibitor could best down-regulate the elevated co-
expression of IL-10 and p-Elk-1 in PBMCs. Because of the low
expression of IL-10 in freshly isolated control PBMCs (Figure S2),
we stimulated control PBMCs with IFN-a, a pivotal cytokine
upregulated in most SLE patients [23], to mimic SLE PBMCs and
incubated them with the MAPK inhibitors specific to ERK (PD
98059), JNK (SP 600125) or p38 (SB 203580), respectively. IFN-a-
stimulation could significantly increase the percentage of IL-10+p-
Elk-1+ cells in B, T cells and monocytes (n = 5, P= 0.0002, 0.0018
and 0.0079, respectively, Figure 4C), and such increase could be
best down-regulated by the addition of the ERK inhibitor
(P= 2.861025, 0.0046 and 0.0079 in B, T cells and monocytes,
respectively, Figure 4C). To a lesser extent, the p38 inhibitor also
significantly suppressed IFN-a-induced double positive cells in all
three cell subsets (P= 0.0016, 0.01 and 0.0039 in B, T cells and
monocytes, respectively). Under our experimental conditions, the
JNK inhibitor significantly inhibited the percentage of IL-10+p-
Elk-1+ cells in B cells and monocytes (P= 0.0048 and 0.009,
respectively), but not in T cells (P= 0.10).
Discussion
Our data provide strong evidence for a dose-dependent
association between SLE-predisposing IL10 genotypes and corre-
sponding mRNA and protein levels of IL-10, and identify one
underlying molecular mechanism to explain previous findings of
elevated IL-10 serum levels in SLE patients that positively
correlated with increased disease activity. In addition to confirm-
ing the previously reported association with SLE at the IL10 39
downstream SNP (rs3024505) in European Americans, we
identified a SLE-associated risk haplotype, defined by the minor
alleles of four SNPs in tight LD, rs3024505, rs3024495, rs3024493
and rs3122605, which could best explain the association with SLE
and capture underlying causal variant(s) within the IL10 gene
cluster in EA ancestry. The minor allele of rs3122605, which tags
the IL10 SLE-risk haplotype, exhibited a dose-dependent associ-
ation with elevated IL10 expression at both mRNA levels in
PBMCs and protein levels in plasma samples from SLE patients
and healthy controls, suggesting that these four SLE-associated
SNPs may act by influencing IL10 regulation. Further functional
studies showed that only rs3122605 was experimentally validated
to confer preferential allele-binding to the transcription factor Elk-
1 present in SLE PBMCs, hence the most likely functional variant
present on the IL10 risk haplotype. Compared to normal PBMCs,
nuclear localization of activated p-Elk-1 was observed only in SLE
PBMCs. Co-expression of p-Elk-1 and IL-10 was significantly
increased in all SLE PBMC subsets compared to normal PBMC
subsets. Of interest, SLE patients with active disease had higher
double positive (p-Elk-1+IL-10+) B cells than those with inactive
disease. These data suggested that nuclear accumulation of
activated Elk-1 in SLE peripheral lymphocytes contributes to
overproduction of IL-10 in SLE patients associated with disease
activity.
An abnormally high production of IL-10 in patients with SLE
has been consistently demonstrated in many studies (reviewed in
[18]), but the underlying molecular mechanism remains less well-
characterized. The observation that healthy relatives of SLE
patients also exhibit increased levels of IL-10 [16,24,25] suggests a
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possibility of genetically regulated IL-10 production. A number of
genetic polymorphisms in the IL10 promoter region have been
reported [26–30], in particular, three SNPs shown in Figure 1D
located at 21082 (rs1800896, C/T), 2819 (rs1800871, G/A) and
2592 (rs1800872, G/T) have been inconsistently associated with
IL-10 production levels and risk of SLE (reviewed in [18,19]).
Identification of SNPs in the 21.3 to 24 kb region of the IL10
promoter associated with both IL-10 production phenotypes and
SLE susceptibility [31] suggested that further evaluating the
contribution of SNPs in the more distal promoter of IL10 might be
warranted. Consistently, the SNP (rs3122605) we identified that
tags the SLE-risk haplotype in EA ancestry and confers genetic
effect on IL10 expression is located at 9.2 kb upstream of IL10.
According to the ENCODE Project, rs3122605, rs3024505,
rs3024493 and rs61815643 were located within DNasel hyper-
sensitive and transcription factor binding sites in at least one cell
type (as shown in UCSC genome browser), suggesting that each of
them may affect gene expression through interaction with
regulatory elements. Given that gene regulation by genetic
variants often occurs within the specific cell types most relevant
to the disease phenotype [32], we used nuclear extracts from
PBMCs of active SLE patients to perform EMSA assays and found
only the SLE-risk allele of rs3122605 preferentially binds to the
transcription factor Elk-1. Therefore, our data support rs3122605
Figure 4. Co-expression of p-Elk-1 and IL-10 in PBMCs. (A) Quantification of co-expression of p-ELK-1 and IL-10 in B cells (CD19+), T cells (CD3+)
and monocytes (CD14+), respectively, by flow cytometry. Numbers in upper quadrants indicate the percentages of double positive (IL-10+p-Elk-1+)
cells. (B) Increased proportions of IL-10+p-Elk-1+ cells in B, T cells and monocytes from SLE patients compared to controls, and increased IL-10+p-Elk-1+
cells in B cells from active compared to inactive SLE patients. Each symbol represents an individual and horizontal lines indicate mean 6 SEM values.
(C) Decreased proportions of IL-10+p-Elk-1+ cells with inhibition of Elk-1 activation. Normal PBMCs were incubated with IFNa in the presence or
absence of MAPK inhibitor ERK (PD 98059), JNK (SP 600125) or p38 (SB 203580), and IL-10+p-Elk-1+ cells were quantified in B, T cells and monocytes,
respectively. Each symbol represents an individual and horizontal lines indicate mean 6 SEM values. P*#0.01, P#,0.005, P**,0.0001 (Student’s t
test) for the comparison of indicated groups.
doi:10.1371/journal.pgen.1003870.g004
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as the most likely causal variant on the SLE-associated haplotype
and implicate a potential importance for Elk-1-mediated upregu-
lation of IL10 expression in SLE patients, particularly in those
patients carrying the risk allele of rs3122605.
Elk-1 is a member of the Ets oncogene family of transcription
factors characterized by a conserved DNA-binding domain and a
C-terminal activation domain containing multiple phosphoryla-
tion sites targeted by three major MAP kinase pathways [33].
Different phosphorylation patterns of Elk-1 mediated through
activation of MAPK signaling cascades by distinct external stimuli
are important for Elk-1 to execute its physiologic functions [34–
37]. We used an antibody to measure phosphorylation of Elk-1 at
S383, and detected the presence of Elk-1 pS383 in the nuclei of
SLE but not normal PBMCs. Quantification of IL-10 and p-Elk-1
co-expression confirmed a higher proportion of IL-10+p-Elk-1+
cells in SLE than normal PBMC subsets. These findings imply that
Elk-1 in nuclei of SLE PBMCs has been biologically activated
likely due to a higher baseline immune activation status, which
may enhance ability of Elk-1 to regulate IL10 transcription. In the
absence of microenvironmental activation in control PBMCs, Elk-
1 remains within the cytoplasm and less translocated into nuclei,
limiting its regulation effects. This hypothesis may in part explain
the observation of higher IL-10 expression in SLE patients than
healthy controls even if they carry the same risk genotype of
rs3122605. In support of this possibility, previous studies revealed
an increased expression of activation markers on peripheral
lymphocytes of SLE patients, including phosphorylated ERK,
JNK and p38 which are prerequisite for subsequent activation of
Elk-1 [38,39]. In addition, our data showed a significantly
increased proportion of IL-10+p-Elk-1+ cells in normal PBMC
subsets (Figure 4C) when exposed to IFN-a which may induce a
partial activation phenotype in lymphocytes mimicking that of
SLE.
We used healthy control, rather than SLE, PBMCs for testing
effects of MAPK inhibitors on co-expression of IL-10 and p-Elk-1,
because disease activity and medications of SLE patients might
confound the results and leucopenia of SLE patients could limit
the amount of PBMCs available for our experiments. In all three
cell subsets of PBMCs, inhibition of ERK could best suppress IFN-
a induced increase in IL-10 and p-Elk-1 co-expression, highlight-
ing the importance for phosphorylated Elk-1 via ERK signaling in
regulation of IL10 transcription. The ERK-dependent activation
of Elk-1 has been clearly demonstrated in neuronal cells (reviewed
in [40]) in which phosphorylation of Elk-1 at S383/389 by ERK is
tightly linked to its activation and nuclear translocation and
inhibition of phosphorylation results in cytoplasmic Elk-1 reten-
tion, limiting its transcriptional properties [22].
Elk-1, like all members of Ets-domain containing transcription
factors, can bind genomic regions similarly as well as uniquely to
regulate distinct classes of target genes [41]. Another member of
the Ets family, Ets-1, has a dual function in regulating IL10 gene
expression acting as both a transcriptional activator with the
binding partner Sp-1 in HIV-1Tat-induced IL10 transcription in
THP-1 cells [42], and as a repressor interacting with histone
deacetylase 1 (HDAC1) in Th1 cells [43]. Increasing evidence
indicates the involvement of Ets-1 in the pathogenesis of SLE: (1)
ETS1 has been identified as a risk locus for SLE in GWAS [44,45]
and the risk allele is associated with decreased levels of ETS1
transcripts in healthy control PBMCs [45]; (2) Ets-1 is critical in
maintaining B cell identity and its absence drives terminal
differentiation of B cells into immunoglobulin-secreting plasma
cells [46,47]; (3) Ets-1 functions as a cofactor for T-bet essential for
Th1 effector function and differentiation [48]; (4) Ets-1 negatively
regulates Th17 cell differentiation and Ets-1 deficiency results in
elevated production of IL-17 and IL-17-related cytokines by Th17
cells [49]. These emerging findings support an important role of
Ets family transcription factors in the development of SLE
manifestations.
Previous findings indicated that increased production of IL-10
by SLE PBMCs was mainly derived from B cells [16,50–53]. One
explanation might be due to elevated expression of toll-like
receptor 9 (TLR9) on B cells of SLE patients with active disease, as
the study showed that TLR9-CpG interaction could enhance the
production of anti-dsDNA antibody and IL-10 [54]. B cell
receptor (BCR) stimulation or BCR-TLR9 costimulation have
been shown to activate the Erk pathway in B cells of NZB6NZW
F1 mice [55]. A plausible explanation of elevated co-expression of
IL-10 and p-Elk-1 in B cells from SLE patients, especially during
active disease, might be attributable to activated ERK and Elk-1
involved in the BCR-dependent IL-10 production in SLE B cells.
Overexpression of B-cell-derived IL-10 contributes to the
pathogenesis of SLE likely dependent on its ability to promote B
cell proliferation, differentiation and autoantibody production
[56,57]. Recently identified IL-10 producing regulatory B cells
(Bregs) may exert immunosuppressive effects to modulate murine
lupus [58–63]. The phenotypic markers of human Breg cells have
not reached consensus; they may be enriched in
CD19+CD24hiCD38hi and CD24hiCD27+ peripheral blood cells
[64,65]. Interestingly, CD19+CD24hiCD38hi B cells from SLE
patients produce less IL-10 upon stimulation and are functionally
impaired in suppressive capacity [64]. Thus, it seems unlikely that
Bregs are the major producer of elevated IL-10 we observed in
SLE patients.
The minor allele of rs3024505 showed consistently higher
frequency in SLE patients than controls in all four ancestries, but
only reached statistical significance for association with SLE in EA.
Upon considering different genetic models, the additive model
yielded the best genotypic association in EA (P= 2.761028, OR
[95%CI] = 1.30 [1.19–1.43]). Given the lack of evidence for
genetic heterogeneity across EA, AS, AA and HS (P= 0.66 for Q
statistic), the lack of significant association between rs3024505 and
risk of SLE in AS, AA and HS might be due to low minor allele
frequency and small sample size. Under the assumption that the
minor allele of rs3024505 confers genetic risk with an odds ratio of
1.3 (determined in EA), the power to detect a significant
association (P,0.05) for EA samples reaches 100%, whereas it is
only 31% in AS, 55% in AA and 58% in HS datasets. According
to the 1000 Genome Project data, the LD strength between
rs3024505 and our proposed causal SNP rs3122605 is similarly
strong in Asians (r2 = 1.0) and Americans/Hispanics (r2 = 0.8) as in
Europeans (r2 = 0.85), but not in Africans (r2 = 0.1), suggesting that
rs3122605 can be tagged by rs3024505 in non-Europeans except
for the African-derived population.
It is possible that other SLE-associated variant(s) specific for AS,
AA or HS failed to be captured by SNPs used in this study due to
different LD pattern in each ancestry. Among non-European
populations, SLE GWAS conducted in AA and HS are not in the
currently available literature. To our knowledge, there have been
four published SLE GWA studies conducted in AS, including two
Chinese [44,45], one Japanese [66] and one Korean GWAS [67],
and a meta-analysis study based on Chinese GWAS [68]. In these
studies, the Illumina Human 610 BeadChip is the commonly used
genotyping platform, which contains nine IL10 SNPs (including
rs3024505) and can capture 23 of the 38 common SNPs
(MAF.1%) within +/25 kb of IL10 with r2.0.9 in Asians
(according to the 1000 Genome Project data). Because none of
these studies have reported association signals of IL10 SNPs with
SLE, current data are consistent with our findings that the IL10
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locus is not a strong genetic risk factor for SLE in AS. Taken
together, the association of IL10 with SLE in non-EA ancestries
awaits further investigation.
We have searched four publically available cis-eQTL datasets
conducted in immune cells from healthy Europeans [69–72] but
found no convincing evidence to support the presence of another
SNP that can better capture the association signal of IL10
expression trait in these datasets than our data of SLE-associated
rs3024505/rs3122605. In addition, there was no convincing
evidence to support the association of rs3024505 with differential
expression of other genes within +/21 Mb flanking region of
IL10.
Given that the SNP rs3024505 confers increased risk for both
SLE and IBD and could be tagged by rs3122605, it is possible that
patients with IBD carrying the risk allele of rs3024505 may exhibit
high serum levels of IL-10. There is evidence supporting elevated
circulating IL-10 levels in both CD and UC patients that positively
associated with disease activity [73–75], similarly to previous
reports in SLE patients. However, genetically engineered mice
exhibiting low to no IL-10 signaling in the intestinal tract develop
severe IBD manifestations [76–78], supporting a pivotal role of IL-
10 in down-regulation of inflammation. Increased levels of
circulating IL-10 may be elicited by chronic inflammation in
IBD, but may not be sufficiently strong to dampen intestinal
inflammation [75], raising the possibility of defective IL-10
signaling at sites of organ damage in patients with SLE.
In conclusion, by characterizing genetic variations within the
IL10 gene cluster region, we have identified the IL10 upstream
SNP rs3122605 as the best likely causal variant responsible for
association with SLE in European Americans. The SLE-associated
rs3122605 G-allele preferentially binds to the activated Elk-1
conferring elevated IL10 expression. The observation that SLE
patients, particular those with increased disease activity, showed
enhanced activation of Elk-1 in nuclei and elevated co-expression
of IL-10 and phospho-Elk-1 in peripheral lymphocytes highlights
the involvement of aberrant Elk-1 signaling in development of
SLE and suggests potential targeting therapy for disease amelio-
ration.
Materials and Methods
Ethics statement
This study was approved by the Institutional Review Boards
(IRBs) or the ethnic committees at the institutions where subjects
were recruited. All subjects were enrolled after informed consent
had been obtained. The overall study was approved by the IRB of
the Oklahoma Medical Research Foundation (OMRF).
Subjects
To test the association of IL10 family genes with SLE, we used a
large collection of case-control subjects from the collaborative
Large Lupus Association Study 2 (LLAS2) [79], including
European American (EA: 4,248 cases vs. 3,818 controls), African
American (AA: 1,724 vs. 2,024), Asian (AS: 1,328 vs. 1,348) and
Hispanic enriched for the Amerindian-European admixture (HS:
1,622 cases vs. 887 controls). African Americans included 286
Gullahs (155 cases vs. 131 controls), who are subjects with African
ancestry. Asians were composed primarily of Koreans (906 cases
and 1,012 controls) but also included Chinese, Japanese,
Taiwanese and Singaporeans. Cases were defined by meeting at
least four of the 1997 American College of Rheumatology (ACR)
revised criteria for the classification of SLE [80].
To test functional consequences of SLE-associated variants,
SLE patients and healthy controls of European ancestry were
recruited at the University of California, Los Angeles and through
the Lupus Family Registry and Repository (LFRR, lupus.omrf.org)
for blood donations.
Genotyping and quality control
DNA samples were processed at the Lupus Genetics Studies
Unit of OMRF. SNP genotyping was performed using an Illumina
custom bead array on the iSCAN instrument for 19 tag SNPs
covering over 135 kb of IL10-IL24 region and 347 admixture
informative markers (AIMs). SNPs meeting the following criteria
were included for subsequent genetic association tests: well-defined
cluster scatter plots, SNP call rate .90%, minor allele frequency
.1%, total proportion missing ,5%, P.0.05 for differential
missing rate between cases and controls, and Hardy-Weinberg
proportion (HWP) test with a P.0.01 in controls and P.0.0001 in
cases.
Subjects with individual genotyping missing rate .10% (due to
low quality), shared identity by descent.0.4 or showing mismatch
between the reported and estimated gender were removed. The
global ancestry of each subject was estimated based on genotype of
AIMs, using principal components analysis (PCA) [81] and
ADMIXMAP [82–84], as described in another LLAS2 study
[85], and then genetic outliers were removed.
Finally, a total of unrelated 15,533 subjects including EA (3,820
cases vs. 3,412 controls), AA (1,670 vs. 1,904; composed of 92.5%
African Americans and 7.5% Gullahs), AS (1,252 vs. 1,249;
composed of 74.6% of Koreans, 16.1% of Chinese and subjects
from Japan and Singapore) and HS (1,445 vs. 781) were analyzed
for 19 SNPs.
SNP imputation
Imputation was performed using IMPUTE 2.1.2 [86], with
SNP genotypes of 379 Europeans (CEU, TSI, GBR, FIN and
IBS), 246 Africans (YRI, ASW and LWK), 286 Asians (CHB, JPT
and CHS) and 181 Americans (MXL, PUR and CLM) from the
1000 Genomes Project (version 3 of the phase 1 integrated data,
March 2012 release) as references in imputation for our EA, AA,
AS and HS subjects, respectively. Imputed genotypes had to meet
the threshold of information score .0.9, as well as the quality
control criteria as described above. After imputation, we obtained
an additional 109 SNPs for EA, 45 for AA, 80 for AS and 64 for
HS (the number varied due to different LD structure) for further
analysis.
Real-time quantitative PCR
Total RNA was purified with TRIzol reagent (Life Technolo-
gies) from PBMCs of EA individuals (58 SLE cases and 55 healthy
controls) and reverse-transcribed into cDNA with SuperScript II
Reverse Transcriptase kit (Life Technologies). Messenger RNA
levels of IL10 and a housekeeping gene RPLP0 were measured by
quantitative real-time PCR using TaqMan assays (IL10 probe:
Hs00961622_m1; RPLP0 probe: Hs99999902_m1, Applied Bio-
systems). All samples were run in triplicate. Relative IL10 mRNA
levels were normalized to that of RPLP0, calculated by the 22DDCt
method and Log10 transformed.
Enzyme-linked immunosorbent assay (ELISA)
Plasma IL-10 levels from 132 SLE patients and 116 healthy
controls of EA ancestry were measured by ELISA (R&D systems).
Cell cultures
To examine whether inhibition of MAPK pathway may affect
co-expression of IL-10 and p-Elk-1, control PBMCs (16106) were
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cultured in growth medium with or without interferon alpha
(IFNa) (1000 U/ml; PBL Biomedical Laboratories) in the presence
or absence of one MAPK inhibitor (EMD Millipore), PD 98059
(20 mM; ERK/MEK inhibitor), SP 600125 (20 mM; JNK inhib-
itor) or SB 203580 (10 mM; p38-MAPK pathway inhibitor),
respectively. Addition of Brefeldin A (eBiosciense) to cells in
culture blocks intracellular protein (IL-10) transport processes.
Flow cytometry
The patients with SLE recruited in this part of study were
evaluated for disease activity by the SLE Disease Activity Index
(SLEDAI) 2000 [87] at the time of blood draw, and SLEDAI$4
was considered as active disease [20,21]. Freshly isolated or
cultured PBMCs were incubated with mouse reference serum to
block nonspecific binding to Fcc receptors and then incubated
with peridinin chlorophyll protein (PerCP)-conjugated anti-human
CD3, allophycocyanin (APC)-conjugated anti-human CD19 and
phycoerythrin (PE)-conjugated anti-human CD14 (eBiosciense) to
identify T cell, B cell and monocyte subpopulations, respectively.
For intracellular staining of IL-10 and p-Elk-1, cells were fixed
with IC Fixation Buffer (eBiosciense), washed with Permeabiliza-
tion Buffer (eBiosciense), and stained with fluorescein isothiocya-
nate (FITC)-conjugated anti-human IL-10 (eBiosciense) and PE-
or Alexa Fluor647-conjugated anti-phospho-Elk-1 antibody (BD
Biosciences). Background fluorescence was assessed using appro-
priate isotype- and fluorochrome-matched control antibodies.
Cells were collected and analyzed by FACSCalibur flow cytometer
equipped with the manufacturer’s software (CellQuest; BD
Biosciences).
Bioinformatic prediction of transcription factors,
electrophoretic mobility shift assay (EMSA) and
supershift assay
Bioinformatic analysis using the program TFSEARCH (con-
ducted on 01/18/2011) showed predicted binding to Elk-1 and
STRE in DNA sequence containing the minor but not the major
allele of rs3122605 (Figure S3 and S4). In addition, HSF, ADR1
and MZF1 were predicted to bind with sequence containing either
allele of rs3122605. Given that we were interested in identifying
transcription factors that preferentially bind to the minor allele of
rs3122605, and that the STRE (stress response element) binding
factor includes two yeast transcription factors, Msn2p and Msn4p,
we prioritized to test Elk-1 using EMSA.
EMSA and supershift assays were performed as previously
described [88]. Nuclear extracts were prepared from peripheral
blood lymphocytes of SLE patients with active disease using NE-
PER Nuclear Extraction Reagent (Thermo scientific) and incu-
bated with biotin-labeled oligodeoxynucleotides (synthesized by
Integrated DNA Technologies, depicted in Table S3). EMSAs
were performed with the LightShift Chemiluminescent EMSA kit
(Thermo scientific). The antibody used in the supershift reactions
was polyclonal rabbit anti-human Elk-1 (Santa Cruz Biotechnol-
ogy).
Immunoblot analyses
Cytoplasmic or nuclear proteins from PBMCs were prepared
using NE-PER Nuclear Extraction Reagent (Thermo scientific).
Following SDS/PAGE, proteins were transferred onto Immobilon-
P membrane (Millipore). After blocking with membrane blocking
solution (Invitrogen, Life Technologies), the membrane was
successively incubated with the anti-Elk-1 (Santa Cruz Biotechnol-
ogy) or anti-phospho-Elk-1 (Cell Signaling Technology) primary
antibody and the horseradish peroxidase (HRP)-conjugated
secondary antibody (Santa Cruz Biotechnology). Blots were
developed using the ECLPlus Western Blotting Detection System
(GE Healthcare), visualized with ChemiDoc XRS imager and
analyzed by Quantity One software (BIO-RAD). b-actin or Lamin
B was used as internal control.
Statistical analysis
Allelic association tests in each ancestral group and conditional
haplotype-based association tests in EA ancestry were performed
by PLINK v1.07 software [89] under a logistic regression model
adjusted for gender and the first three principal components
estimated using AIMs. The Bonferroni corrected P-value threshold
was adjusted to P,3.961024 ( = 0.05/128 SNPs in EA). Pairwised
LD values between SNPs and haplotypic association with SLE
were evaluated using Haploview 4.2 [90]. The linear regression
test was used to evaluate the association of SNP genotypes with IL-
10 mRNA or protein levels. The Student’s t-test was used to
compare the mean values between two groups. A P value,0.05
was considered to be statistically significant.
Supporting Information
Figure S1 No nuclear protein bindings conferred by rs3024505,
rs3024493, rs3024495 and rs61815643. In EMSA, oligodeoxynu-
cleotide probes containing the risk and non-risk alleles of
rs3024505 (A), rs3024493 (B), rs3024495 (C) and rs61815643 (D)
were incubated with nuclear extracts of peripheral blood
lymphocytes from active SLE patients. Competition analysis using
excess amounts of unlabeled self-competitor confirmed that shift
bands produced by probes of rs3024493 and rs61815643 were not
specific (N.S.). The data are representative of two independent
experiments.
(TIF)
Figure S2 IL-10 expression in T cells, B cells and monocytes.
Representative contour plot and quantification of IL-10-producing
CD3+ T cells, CD19+ B cells and CD14+ monocytes in (A) normal
PBMCs treated with or without IFNa for 24 hours, and in (B)
PBMCs from patients with SLE. (C) CD19-gated PBMC
population was used for the purity of B cells. The gate indicates
the percentage of IL-10 producing B cells from patients with SLE.
Data are represented as mean 6 SD percentage of positive cells
obtained in three independent experiments using different
individuals.
(TIF)
Figure S3 TFSEARCH search result of the SLE-risk minor
allele of rs3122605.
(TIF)
Figure S4 TFSEARCH search result of the major allele of
rs3122605.
(TIF)
Table S1 Association of IL10 SNPs with SLE in European
Americans. Position of each SNP is based on GRch37/hg19. Only
SNPs with P,0.05 were tested in conditional testing. Four SLE-
associated IL10 SNPs are highlighted in bold. Abbreviation: G,
genotyped; I, imputed; ND, not distinguished; OR, odds ratio; -,
missing data.
(DOC)
Table S2 Association of IL10 cluster SNPs with SLE in Non-
European ancestral groups. Position of each SNP is based on
GRch37/hg19. Missing data in SNP imputation is denoted as ‘–’.
Four SLE-associated SNPs identified in European Americans are
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highlighted in bold. Abbreviation: G, genotyped; I, imputed; OR,
odds ratio.
(DOC)
Table S3 DNA sequences of oligodeoxynucleotide probes used
in EMSA.
(DOC)
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